Intravitreal Bevacizumab nanoparticles ameliorates retinal vasculopathy in an in vivo mouse model of retinopathy of prematurity
Retinopathy of Prematurity is treated with anti-vascular endothelial growth factor drugs such as Bevacizumab. Anti-VEGF drugs result in systemic toxicity from repeat dosing due to their short half-life. We, for the first time, show the feasibility and optimization of nanoparticle formulation of bevacizumab in a mouse model of ROP. Intravitreal Bevacizumab nanoparticles may prevent systemic toxicity and improve outcomes in infants with ROP.
Authors
- Srinivasan Raghunathan (ORCID: https://orcid.org/0000-0002-2782-3520)
- Olachi J. Mezu‐Ndubuisi (ORCID: https://orcid.org/0000-0002-6930-1747)
- Alfiya Raja
- Ben Amadi
Institutions
- University of Rochester Medical Center (US)
- University of Rochester (US)
Publication Details
- Journal
- Pediatric Research
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1038/s41390-025-04508-w
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Rochester
- National Institutes of Health
- National Eye Institute